Anebulo Pharmaceuticals Inc
NASDAQ:ANEB

  • LAST PRICE
    1.4600
  • TODAY'S CHANGE (%)
    -0.0400 (-2.6667%)
  • Bid / Lots
    1.4500/ 1
  • Ask / Lots
    1.5900/ 18
  • Open / Previous Close
    1.4800 / 1.5000
  • Day Range
    1.4200
    1.5800
  • 52 Week Range
    1.2500
    3.3000
  • Volume
    3,491

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 19, 2024

  • Nov 13, 2024

      Show headlines and story abstract

    • 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
      Companies Mentioned: ANEB

      or otherwise after the date of this press release.
      Condensed Balance Sheets June 30, September 30, 2024 2024 -------------------- ---------- Cash and cash equivalents $ 1,404,211 $3,094,200 Total assets 2,467,940 4,073,114 Total liabilities 569,225 260,583 Total stockholders' equity 1,898,715 3,812,531 Condensed Statements of Operations Three months ended September 30, -------------------------------------- 2024 2023 ------------------ -------------- Research and development $ 1,314,859 $ 1,270,220 General and administrative 1,097,265 1,273,458 -------------- ------------- Total operating expenses 2,412,124 2,543,678 -------------- ------------- Loss from operations (2,412,124) (2,543,678) Other (income) expenses: Interest expense 59,697 - Interest income (26,006) (55,198) Grant income (245,362) - Other 283 (7,657) -------------- ------------- Total other income, net (211,388) (62,855) -------------- ------------- Net loss $ (2,200,736) $ (2,480,823) ============== ============= Weighted average common shares outstanding, basic and diluted 25,933,217 25,633,217 ============== ============= Net loss per share, basic and diluted $ (0.08) $ (0.10) ============== =============

    • 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
      Companies Mentioned: ANEB

      or otherwise after the date of this press release.
      Condensed Balance Sheets June 30, September 30, 2024 2024 -------------------- ---------- Cash and cash equivalents $ 1,404,211 $3,094,200 Total assets 2,467,940 4,073,114 Total liabilities 569,225 260,583 Total stockholders' equity 1,898,715 3,812,531 Condensed Statements of Operations Three months ended September 30, -------------------------------------- 2024 2023 ------------------ -------------- Research and development $ 1,314,859 $ 1,270,220 General and administrative 1,097,265 1,273,458 -------------- ------------- Total operating expenses 2,412,124 2,543,678 -------------- ------------- Loss from operations (2,412,124) (2,543,678) Other (income) expenses: Interest expense 59,697 - Interest income (26,006) (55,198) Grant income (245,362) - Other 283 (7,657) -------------- ------------- Total other income, net (211,388) (62,855) -------------- ------------- Net loss $ (2,200,736) $ (2,480,823) ============== ============= Weighted average common shares outstanding, basic and diluted 25,933,217 25,633,217 ============== ============= Net loss per share, basic and diluted $ (0.08) $ (0.10) ============== =============

Peers Headlines